Patents by Inventor Wolfgang Wrasidlo
Wolfgang Wrasidlo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100278811Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: ApplicationFiled: December 1, 2009Publication date: November 4, 2010Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Publication number: 20100266675Abstract: The invention provides novel compositions—lipopeptides and analogs, including somocystinamide A, and somocystinamide A variants and analogs, and pharmaceutical compositions, liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these lipopeptides and analogs are used to induce apoptosis in a cell, which can be a normal cell, a dysfunctional cell and/or a cancer (tumor) cell. In alternative embodiments, the compositions of the invention, including the lipopeptides and analogs of the invention, and the pharmaceutical compositions comprising them, are used to treat or ameliorate (including slowing the progression of) normal, dysfunctional (e.g., abnormally proliferating) and/or tumor associated blood vessels, including endothelial and/or capillary cell growth; including neovasculature related to (within, providing a blood supply to) a tumor.Type: ApplicationFiled: May 21, 2008Publication date: October 21, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: William Gerwick, Wolfgang Wrasidlo, Dennis Carson, Dwayne Stupack, Takashi Suyama
-
Publication number: 20100226969Abstract: The invention provides compositions comprising protein aggregation inhibitors, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for preventing, reversing, slowing or inhibiting protein aggregation, e.g., for treating diseases that are characterized by protein aggregation—including some degenerative neurological diseases such as Parkinson's disease. In one aspect, the compositions of the invention specifically target synuclein, beta-amyloid and/or tau protein aggregates, and the methods of the invention can be used to specifically prevent, reverse, slow or inhibit synuclein, beta-amyloid and/or tau protein aggregation. In alternative embodiments, the compositions and methods of the invention, are used to treat, prevent or ameliorate (including slowing the progression of) degenerative neurological diseases related to or caused by protein aggregation, e.g., synuclein, beta-amyloid and/or tau protein aggregation.Type: ApplicationFiled: June 13, 2008Publication date: September 9, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Eliezer Masliah, Igor Tsigelny, Wolfgang Wrasidlo, Edward Rockenstein
-
Publication number: 20100209488Abstract: The invention provides compositions, e.g., small molecules, that disrupt the activity of protein kinases, including constitutively activated protein kinases, such as kinases constitutively activated through mutations, and kinases in their native inactivated state, and methods for making and using them. In one aspect, compositions of the invention bind a protein kinase in its inactive conformation involving the conserved asparagine-phenylalanine-glycine residue motif, or “Asp-Phe-Gly” or “DFG” motif, of the activation loop in the allosteric binding site. The small molecule protein kinase inhibitors of the invention comprise or are derivatives or analogs of oxadiazoles, thiadiazoles, oxazoles, thiazoles, arylamides, quinolones, pyrazoles, pyrazolones, imides, pyrolles, imidazoles and/or triazoles.Type: ApplicationFiled: July 15, 2008Publication date: August 19, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Wolfgang Wrasidlo, Eric Murphy, David Cheresh
-
Publication number: 20100203113Abstract: The invention provides dBHD-based compositions and dBHD analog compositions, and pharmaceutical compositions comprising them, e.g., in the form of liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these dBHD analogs are used to inhibit a dysfunctional stem cell and/or a cancer (tumor) stem cell.Type: ApplicationFiled: May 15, 2008Publication date: August 12, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Wolfgang Wrasidlo, Catriona H. Jamieson, Dennis Carson, Tadeusz F. Molinski, Desheng Lu
-
Patent number: 7652051Abstract: Heterocyclic compounds derived from benzotriazine, triazines, triazoles and oxadiazoles are disclosed. The methods of synthesis and of use of such heterocyclic compounds are also provided.Type: GrantFiled: August 24, 2005Date of Patent: January 26, 2010Assignee: TargeGen, Inc.Inventors: Wolfgang Wrasidlo, Elena Dneprovskaia
-
Publication number: 20090275569Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.Type: ApplicationFiled: September 9, 2008Publication date: November 5, 2009Inventors: Xianchang Gong, Kathy Barrett, Jianguo Cao, Colleen Gritzen, Glenn Noronha, John D. Hood, Chi Ching Mak, Andrew McPherson, Ved Prakash Pathak, Joel Renick, Richard M. Soll, Ute Splittgerber, Wolfgang Wrasidlo, Ningning Zhao, Elena Dneprovskaia, Binqi Zeng, Glenn Noronha
-
Patent number: 7582778Abstract: The invention relates to podophyllotoxins, uses thereof and methods of their production.Type: GrantFiled: December 3, 2002Date of Patent: September 1, 2009Assignee: Universitatsklinikum Charite der Humboldt-Universitat zuInventors: Gerhard Gaedicke, Holger N. Lode, Wolfgang Wrasidlo
-
Patent number: 7456176Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.Type: GrantFiled: April 7, 2005Date of Patent: November 25, 2008Assignee: TargeGen, Inc.Inventors: Glenn Noronha, Kathy Barrett, Jianguo Cao, Colleen Gritzen, Xianchang Gong, John D. Hood, Chi Ching Mak, Andrew McPherson, Ved Prakash Pathak, Joel Renick, Richard M. Soll, Ute Splittgerber, Wolfgang Wrasidlo, Binqi Zeng, Ningning Zhao, Elena Dneprovskaia
-
Publication number: 20070208019Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: ApplicationFiled: January 11, 2007Publication date: September 6, 2007Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Patent number: 7208493Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: GrantFiled: October 2, 2003Date of Patent: April 24, 2007Assignee: TargeGen, Inc.Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Publication number: 20060293254Abstract: The invention relates to podophyllotoxins, uses thereof and methods of their production.Type: ApplicationFiled: December 3, 2002Publication date: December 28, 2006Inventors: Gerhard Gaedicke, Holger Lode, Wolfgang Wrasidlo
-
Publication number: 20060079526Abstract: Heterocyclic compounds derived from benzotriazine, triazines, triazoles and oxadiazoles are disclosed. The methods of synthesis and of use of such heterocyclic compounds are also provided.Type: ApplicationFiled: August 24, 2005Publication date: April 13, 2006Applicant: TargeGen, Inc.Inventors: Wolfgang Wrasidlo, Elena Dneprovskaia
-
Publication number: 20050282814Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: ApplicationFiled: April 13, 2005Publication date: December 22, 2005Applicant: TargeGen, Inc.Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Publication number: 20040167198Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: ApplicationFiled: October 2, 2003Publication date: August 26, 2004Applicant: TargeGen, Inc.Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Patent number: 6534041Abstract: The invention relates to acid-labile and enzymatically divisible compounds for in-vivo and in-vitro diagnosis by means of near infrared radiation (NIR-radiation), the use of said compounds as optic diagnostic and therapeutic agents, and the diagnostic agents containing said compounds.Type: GrantFiled: May 1, 2000Date of Patent: March 18, 2003Assignee: Institute for Diagnostic Research GmbH of the Free University of BerlinInventors: Kai Licha, Bjorn Riefke, Wolfhard Semmler, Wolfgang Wrasidlo
-
Patent number: 6271384Abstract: Onium salts of taxo-diterpenoid-Cn,2-O-aza-arenes form water soluble self-assembling nanostructures above a critical aggregation concentration. The onium salt of aza-arene includes a delocalized charge which renders derivatized taxo-diterpenoids amphoteric, enhances their solubility in water, and promotes self-assembly of water soluble nanostructures, e.g., helical fibular structures and spherical micellular structures. These same onium salts of taxo-diterpenoid-Cn,2-O-aza-arenes are employed as water soluble prodrugs. For example, taxol-2′-methylpyridinium tosylate (MPT) is characterized by an elevated aqueous solubility, rapid activation by serum protein, good stability in most other aqueous solutions, formation of a protein:taxol intermediate and good retention within the circulatory system. The toxicity of the activated form is comparable or greater than underivatized taxol. Furthermore, taxol-2′-MPT can be synthesized by a simple one step reaction between taxol and 2-fluoro-1-MPT.Type: GrantFiled: April 13, 1998Date of Patent: August 7, 2001Assignee: The Scripps Research InstituteInventors: K. C. Nicolaou, Wolfgang Wrasidlo, Rodney K. Guy, Emmanuel Pitsinos
-
Patent number: 6252094Abstract: Cyclic chemical switching method is employed for solubilizing and desolubilizing taxo-diterpenoids with respect to aqueous solvents. 2-Halogenated onium salts of aza-arenes are employed to derivatize taxo-diterpenoids so as to alter their solubility in aqueous solvents. The onium salt of aza-arene includes a delocalized charge which imparts polarity and aqueous solubility to taxo-diterpenoid derivatives. Solubilization is achieved in a one step derivatization with the onium salt of 2-halogenated aza-arenes. Desolubilization is achieved by contacting onium salts of taxo-diterpenoid-Cn,2-O-aza-arenes with serum protein to displace the 2-O-aza-arene and form a soluble protein:taxo-diterpenoid intermediate. This protein:taxo-diterpenoid intermediate then dissociates over time to provide a bioactive taxo-diterpenoid. These same onium salts of taxo-diterpenoid-Cn,2-O-aza-arenes are employed as water soluble prodrugs. The toxicity of the activated form is comparable or greater than underivatized taxol.Type: GrantFiled: February 4, 1999Date of Patent: June 26, 2001Assignee: The Scripps Research InstituteInventors: K. C. Nicolaou, Wolfgang Wrasidlo, Rodney K. Guy, Emmanuel Pitsinos
-
Patent number: 6025491Abstract: Onium salts of taxo-diterpenoid-C.sup.n, 2-0-aza-arenes are employed as water soluble prodrugs. For example, taxol-2'-methylpyridiniumtosylate (MPT) is characterized by an elevated aqueous solubility, rapid activation by serum protein, good stability in most other aqueous solutions, formation of a protein:taxol intermediate and good retension within the circulatory system. The toxicity of the activated form is comparable or greater than underivatized taxol. Furthermore, taxol-2'-MPT can be synthesized by a simple one step reaction between taxol and 2-fluoro-1-MPT. The invention is applicable to taxol and taxol mimetics having hydroxyls that are reactive with onium salts of 2-halogenated-aza-arenes. For example, taxol, C-2 substituted analogs of taxol, and Taxotere each have reactive hydroxyls at the 2' and 7 positions. The invention is also applicable to a wide array of 2-halogenated-aza-arenes.Type: GrantFiled: December 14, 1998Date of Patent: February 15, 2000Assignee: The Scripps Research InstituteInventors: Kyriacos C. Nicolaou, Wolfgang Wrasidlo, Rodney K. Guy, Emmanuel Pitsinos
-
Patent number: 5731334Abstract: C-2'-methylpyridinium acetates (MPA)-taxol and C-2'-methylpyridinium acetates (MPA)-taxotere are prodrugs having good aqueous solubility, low toxiticity and high anti-minor activity. These prodrugs are administered to patients for treating minors. Adminstration may be by injection or infusion.Type: GrantFiled: October 27, 1995Date of Patent: March 24, 1998Assignee: The Scripps Research InstituteInventor: Wolfgang Wrasidlo